Vulvar squamous cell carcinoma in women 80 years and older : Treatment, survival and impact of comorbidities
Copyright © 2023. Published by Elsevier Inc..
BACKGROUND: Despite being a disease of mainly older women, little is known about the clinical management of older women with vulvar squamous cell carcinoma (VSCC). We evaluated their daily clinical management compared with younger women, and established the prevalence of comorbidities and its impact on overall survival (OS).
METHODS: All Dutch women diagnosed with VSCC from 2015 to 2020 (n = 2249) were selected from the Netherlands Cancer Registry. Women aged ≥80 years (n = 632, 28%) were defined as "older" patients, women <80 years were considered as "younger". Chi-square tests were performed to evaluate differences in treatment by age group and comorbidities. Differences in OS were evaluated using Kaplan-Meier Curves and log-rank test.
RESULTS: The vast majority of both older (91%) and younger (99%) patients with FIGO IA VSCC received surgical treatment of the vulva. Older FIGO IB-IV VSCC patients were less likely to undergo groin surgery than younger patients (50% vs. 84%, p < 0.01). Performance of surgical treatment of the vulva and groin(s) was not associated with the number of comorbidities in older patients (p = 0.67 and p = 0.69). Older patients with ≥2 comorbidities did have poorer OS compared to women with one or no comorbidities (p < 0.01).
CONCLUSION: The vast majority of older patients underwent vulvar/local surgery. Older patients less often received groin surgery compared to younger patients. The majority of older patients had at least one comorbidity, but this did not impact treatment choice. The poorer survival in older VSCC patients may therefore be due to death of competing risks instead of VSCC itself.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:179 |
|---|---|
| Enthalten in: |
Gynecologic oncology - 179(2023) vom: 21. Dez., Seite 91-96 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schuurman, Melinda S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aged |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 18.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ygyno.2023.10.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364427035 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364427035 | ||
| 003 | DE-627 | ||
| 005 | 20231227133725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygyno.2023.10.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM364427035 | ||
| 035 | |a (NLM)37951042 | ||
| 035 | |a (PII)S0090-8258(23)01507-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schuurman, Melinda S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vulvar squamous cell carcinoma in women 80 years and older |b Treatment, survival and impact of comorbidities |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 18.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Despite being a disease of mainly older women, little is known about the clinical management of older women with vulvar squamous cell carcinoma (VSCC). We evaluated their daily clinical management compared with younger women, and established the prevalence of comorbidities and its impact on overall survival (OS) | ||
| 520 | |a METHODS: All Dutch women diagnosed with VSCC from 2015 to 2020 (n = 2249) were selected from the Netherlands Cancer Registry. Women aged ≥80 years (n = 632, 28%) were defined as "older" patients, women <80 years were considered as "younger". Chi-square tests were performed to evaluate differences in treatment by age group and comorbidities. Differences in OS were evaluated using Kaplan-Meier Curves and log-rank test | ||
| 520 | |a RESULTS: The vast majority of both older (91%) and younger (99%) patients with FIGO IA VSCC received surgical treatment of the vulva. Older FIGO IB-IV VSCC patients were less likely to undergo groin surgery than younger patients (50% vs. 84%, p < 0.01). Performance of surgical treatment of the vulva and groin(s) was not associated with the number of comorbidities in older patients (p = 0.67 and p = 0.69). Older patients with ≥2 comorbidities did have poorer OS compared to women with one or no comorbidities (p < 0.01) | ||
| 520 | |a CONCLUSION: The vast majority of older patients underwent vulvar/local surgery. Older patients less often received groin surgery compared to younger patients. The majority of older patients had at least one comorbidity, but this did not impact treatment choice. The poorer survival in older VSCC patients may therefore be due to death of competing risks instead of VSCC itself | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Comorbidity | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Vulvar squamous cell carcinoma | |
| 700 | 1 | |a Veldmate, Guus |e verfasserin |4 aut | |
| 700 | 1 | |a Ebisch, Renée M F |e verfasserin |4 aut | |
| 700 | 1 | |a de Hullu, Joanne A |e verfasserin |4 aut | |
| 700 | 1 | |a Lemmens, Valery E P P |e verfasserin |4 aut | |
| 700 | 1 | |a van der Aa, Maaike A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecologic oncology |d 1972 |g 179(2023) vom: 21. Dez., Seite 91-96 |w (DE-627)NLM000614610 |x 1095-6859 |7 nnns |
| 773 | 1 | 8 | |g volume:179 |g year:2023 |g day:21 |g month:12 |g pages:91-96 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ygyno.2023.10.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 179 |j 2023 |b 21 |c 12 |h 91-96 | ||